BLCO Stock Forecast & Price Target

Bausch & Lomb has demonstrated strong revenue growth across all three segments in the third quarter of 2025, with Vision Care revenue reaching $736 million (up 8% year-over-year), Surgical revenue at $215 million (up 4% year-over-year), and Pharmaceuticals revenue totaling $330 million (up 8% year-over-year). The company has regained momentum in premium intraocular lenses, and the ophthalmic pharmaceutical product MIEBO shows exceptional potential, with a remarkable 110% year-over-year prescription growth, indicating a strong market demand. Despite recording a net loss of $28 million, which was significantly lower than anticipated, management has reiterated its positive guidance for 2025, suggesting a solid trajectory for future profitability.

Bausch & Lomb faces significant challenges in maintaining its leadership position in the highly competitive ophthalmology market, compounded by a limited product pipeline and insufficient investment during its time as a subsidiary of Bausch Health. The company is also grappling with macroeconomic uncertainties that may negatively impact consumer spending on contact lenses and elective procedures, particularly cataract surgeries, which can further hinder revenue growth. Additionally, Bausch & Lomb's relatively high leverage post-acquisition of Xiidra could restrict opportunities for future mergers and acquisitions aimed at boosting long-term growth, while ongoing litigation concerning its former parent company could create further investor uncertainty.